ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal study of patients with extra-pancreatic neuroendocrine ...

More representative trial populations and standardized subgroup reporting are needed in non–small cell lung cancer (NSCLC) research, according to a meta-analysis published in Cancers, which found no ...

New subgroup analysis shows consistent, clinically meaningful pain reduction observed from Stage 2 through Stage 4 disease, including late-stage ...

Exelixis, Inc. today announced results from a subgroup analysis of the CABINET phase 3 pivotal trial evaluating CABOMETYX ® versus placebo in patients with previously treated advanced neuroendocrine ...

EORTC QLQ-C30 subgroup results confirm broad and durable quality-of-life improvements across disease stages and metastasis status, complementing previously reported pain reduction and opioid-free ...

Introduction Many neonatal deaths are avoidable using existing low-cost evidence-based interventions. This study evaluated ...

MONTPELLIER, France--(BUSINESS WIRE)--Analysis of a major subgroup of patients undergoing a first Total Knee Replacement (TKR), representing over 70% of the trial population (108 out of 151), revealed ...

We review Bayesian and Bayesian decision theoretic approaches to subgroup analysis and applications to subgroup-based adaptive clinical trial designs. Subgroup analysis refers to inference about ...

Background. A 9-valent human papillomavirus-6/11/16/18/31/33/45/52/58 (9vHPV) vaccine extends coverage to 5 next most common oncogenic types (31/33/45/52/58) in ...

Eligibility criteria for selecting studies We included cohort studies that explored the association between walking speed and the risk of type 2 diabetes in adults. We used random-effects ...